A randomized, double-blind, placebo managed, section III medical trial evaluated the efficacy and safety profile of adalimumab for a monotherapy in sufferers with RA who experienced unsuccessful to respond to csDMARDs [191]. The results showed equally statistically significant improvement in the disease exercise and a very good basic safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/